ValuEngine cut shares of Endocyte (NASDAQ:ECYT) from a sell rating to a strong sell rating in a research note released on Thursday.

ECYT has been the subject of a number of other reports. Wedbush raised Endocyte from a neutral rating to an outperform rating and raised their target price for the stock from $2.00 to $7.00 in a research report on Tuesday, October 3rd. Zacks Investment Research raised Endocyte from a sell rating to a hold rating in a research report on Thursday, November 9th. Finally, Cowen reissued a hold rating on shares of Endocyte in a research report on Monday, October 2nd.

Shares of Endocyte (NASDAQ ECYT) opened at $4.25 on Thursday. The company has a market capitalization of $182.66, a price-to-earnings ratio of -3.15 and a beta of 2.20. Endocyte has a fifty-two week low of $1.17 and a fifty-two week high of $6.55.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.20). The business had revenue of $0.03 million for the quarter. Endocyte had a negative return on equity of 38.91% and a negative net margin of 82,235.72%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) EPS. equities analysts expect that Endocyte will post -1.24 EPS for the current fiscal year.

In other news, VP Christopher P. Leamon sold 23,231 shares of Endocyte stock in a transaction on Friday, December 1st. The stock was sold at an average price of $5.04, for a total value of $117,084.24. Following the completion of the transaction, the vice president now directly owns 150,579 shares in the company, valued at $758,918.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Philip S. Low purchased 5,600 shares of Endocyte stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $4.84 per share, with a total value of $27,104.00. Following the completion of the transaction, the insider now owns 283,005 shares of the company’s stock, valued at approximately $1,369,744.20. The disclosure for this purchase can be found here. Company insiders own 14.86% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in shares of Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 25,003 shares in the last quarter. FMR LLC grew its position in shares of Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after purchasing an additional 31,168 shares in the last quarter. LMR Partners LLP purchased a new position in shares of Endocyte in the second quarter valued at $196,000. Renaissance Technologies LLC grew its position in shares of Endocyte by 284.4% in the first quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 142,461 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Endocyte by 1,064.3% in the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after purchasing an additional 393,975 shares in the last quarter. Institutional investors own 17.58% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://theolympiareport.com/2017/12/25/endocyte-ecyt-downgraded-by-valuengine-to-strong-sell.html.

About Endocyte

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.